View Item 

Show simple item record

Outcomes after hepatic encephalopathy in population- based cohorts of patients with cirrhosis
dc.contributor.authorTapper, Elliot B.
dc.contributor.authorAberasturi, Devin
dc.contributor.authorZhao, Zhe
dc.contributor.authorHsu, Chia‐yang
dc.contributor.authorParikh, Neehar D.
dc.date.accessioned2020-06-03T15:23:44Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-06-03T15:23:44Z
dc.date.issued2020-06
dc.identifier.citationTapper, Elliot B.; Aberasturi, Devin; Zhao, Zhe; Hsu, Chia‐yang ; Parikh, Neehar D. (2020). "Outcomes after hepatic encephalopathy in population- based cohorts of patients with cirrhosis." Alimentary Pharmacology & Therapeutics 51(12): 1397-1405.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/155524
dc.publisherWiley Periodicals, Inc.
dc.titleOutcomes after hepatic encephalopathy in population- based cohorts of patients with cirrhosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155524/1/apt15749.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155524/2/apt15749_am.pdf
dc.identifier.doi10.1111/apt.15749
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceTapper EB, Risech- Neyman Y, Sengupta N. Psychoactive medications increase the risk of falls and fall- related injuries in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol. 2015; 13: 1670 - 1675.
dc.identifier.citedreferenceRe VL, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver- related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011; 20: 689 - 699.
dc.identifier.citedreferenceTapper EB, Korovaichuk S, Baki J, et al. Identifying patients with hepatic encephalopathy using administrative data in the ICD- 10 era. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.12.017 [Epub ahead of print].
dc.identifier.citedreferenceDeyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD- 9- CM administrative databases. J Clin Epidemiol. 1992; 45: 613 - 619.
dc.identifier.citedreferenceMellinger JL, Shedden K, Winder GS, et al. The High Burden Of Alcoholic Cirrhosis In Privately Insured Persons in the United States. Hepatology. 2018; 68: 872 - 882
dc.identifier.citedreferenceAllen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year- community study. Hepatology. 2018; 67: 1726 - 1736.
dc.identifier.citedreferenceTapper EB, Finkelstein D, Mittleman MA, et al. A quality improvement initiative reduces 30- day rate of readmission for patients with cirrhosis. Clin Gastroenterol Hepatol. 2016; 14: 753 - 759.
dc.identifier.citedreferenceAnderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1: 710 - 719.
dc.identifier.citedreferenceFine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 - 509.
dc.identifier.citedreferenceBajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009; 50: 1175 - 1183.
dc.identifier.citedreferenceAmpuero J, Simón M, Montoliú C, et al. Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. Gastroenterology. 2015; 149: 1483 - 1489.
dc.identifier.citedreferenceBustamante J, Rimola A, Ventura P- J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999; 30: 890 - 895.
dc.identifier.citedreferenceMellinger JL, Moser S, Welsh DE, et al. Access to subspecialty care and survival among patients with liver disease. Am J Gastroenterol. 2016; 111: 838.
dc.identifier.citedreferenceSu GL, Glass L, Tapper EB, et al. Virtual consultations through the Veterans administration SCAN- ECHO project improves survival for Veterans with liver disease. Hepatology. 2018; 68: 2317 - 2324.
dc.identifier.citedreferenceTapper EB, Parikh ND, Green PK, et al. Reduced Incidence of hepatic encephalopathy and higher odds of resolution associated with eradication of HCV infection. Clin Gastroenterol Hepatol. 2020; 18: 1197 - 1206.
dc.identifier.citedreferenceVolk ML, Tocco RS, Bazick J, et al. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012; 107: 247.
dc.identifier.citedreferenceBajaj JS, O- Leary JG, Tandon P, et al. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi- centre cohort. Aliment Pharmacol Therap. 2019; 49: 1518 - 1527.
dc.identifier.citedreferenceMorando F, Maresio G, Piano S, et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol. 2013; 59: 257 - 264.
dc.identifier.citedreferenceMellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol. 2013; 11: 217 - 223.
dc.identifier.citedreferenceBeste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001- 2013. Gastroenterology. 2015; 149: 1471 - 1482.e5.
dc.identifier.citedreferenceEstes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018; 67: 123 - 133
dc.identifier.citedreferenceMoon A, Green P, Berry K, et al. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther. 2017; 45: 1201 - 1212.
dc.identifier.citedreferenceParikh ND, Marrero WJ, Wang J, et al. Projected increase in obesity and non- alcoholic steatohepatitis- related liver transplantation waitlist additions in the United States. Hepatology. 2019; 70: 487 - 495.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9: 524 - 530.e1.
dc.identifier.citedreferenceTapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999- 2016: observational study. BMJ. 2018; 362: k2817.
dc.identifier.citedreferenceMoon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.07.060 [Epub ahead of print].
dc.identifier.citedreferenceGomez EV, Rodriguez YS, Bertot LC, et al. The natural history of compensated HCV- related cirrhosis: a prospective long- term study. J Hepatol. 2013; 58: 434 - 444.
dc.identifier.citedreferenceDienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011; 54: 396 - 405.
dc.identifier.citedreferenceKonerman MA, Zhang Y, Zhu J, et al. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology. 2015; 61: 1832 - 1841.
dc.identifier.citedreferenceGinés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7: 122 - 128.
dc.identifier.citedreferenceJepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: A Danish population- based cohort study. Hepatology. 2010; 51: 1675 - 1682.
dc.identifier.citedreferenceTapper EB, Parikh N, Sengupta N, et al. A risk score to predict the development of hepatic encephalopathy in a population- based cohort of patients with cirrhosis. Hepatology. 2018; 68: 1498 - 1507.
dc.identifier.citedreferenceBajaj JS, O- Leary JG, Tandon P, et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol. 2017; 15: 565 - 574.e4.
dc.identifier.citedreferencePatidar KR, Thacker LR, Wade JB, et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014; 109: 1757.
dc.identifier.citedreferenceEzaz G, Murphy SL, Mellinger J, et al. Increased morbidity and mortality associated with falls among patients with cirrhosis. Am J Med. 2018; 131: 645 - 650.
dc.identifier.citedreferenceTapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population- based cohort study. Clin Gastroenterol Hepatol. 2016; 14: 1181 - 1188.
dc.identifier.citedreferenceTapper EB, Henderson JB, Parikh ND, et al. Incidence of and risk factors for hepatic encephalopathy in a population- based cohort of americans with cirrhosis. hepatology. Communications. 2019; 3: 1510 - 1519.
dc.identifier.citedreferenceScaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States. J Clin Gastroenterol. 2015; 49: 690 - 696.
dc.identifier.citedreferenceSharpton SR, Feng S, Hameed B, et al. Combined effects of recipient age and model for end- stage liver disease score on liver transplantation outcomes. Transplantation. 2014; 98: 557.
dc.identifier.citedreferenceBass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362: 1071 - 1081.
dc.identifier.citedreferenceBajaj JS, Acharya C, Fagan A, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis. Am J Gastroenterol. 2018; 113: 1177 - 1186.
dc.identifier.citedreferenceTapper EB, Hao S, Lin M, et al. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology. 2020; 71: 225 - 234.
dc.identifier.citedreferenceSharma BC, Sharma P, Lunia MK, et al. A randomized, double- blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013; 108: 1458 - 1463.
dc.identifier.citedreferenceSalehi S, Tranah TH, Lim S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all- cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019; 50: 435 - 441.
dc.identifier.citedreferenceKimer N, Krag A, Møller S, et al. Systematic review with meta- analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther. 2014; 40: 123 - 132.
dc.identifier.citedreferenceRakoski MO, McCammon RJ, Piette JD, et al. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology. 2012; 55: 184 - 191.
dc.identifier.citedreferenceNehra MS, Ma Y, Clark C, et al. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013; 47: e50.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt15749.pdf
Size:
549.8KB
Format:
PDF
View/Open
Name:
apt15749_am.pdf
Size:
334.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.